News Press release EPFL

Old News Is Good News for TB Drug Discovery

© ghi.epfl.ch/

19.09.12 - Researchers look back to a 1950s antibiotic to combat drug resistance

EPFL researchers have opened the door to a new strategy to fight tuberculosis, the second leading cause of death from infectious disease after HIV. In a study published in EMBO Molecular Medicine on September 17th, EPFL professor Stewart Cole takes a hard look at the natural product pyridomycin, first reported in the 1950s, and determines exactly how it kills Mycobacterium tuberculosis. Pyridomycin inhibits a vital enzyme, much like the best frontline antibiotics, but in a sufficiently different way so it can combat even the most antibiotic-resistant strains that have recently afflicted Russia, South Africa and North America.

“We’ve rediscovered an old antibiotic that was never developed but may lead the way to treating both drug-sensitive and drug-resistant strains of TB. And above all, the strategy of revisiting antibiotics to find new leads looks like a successful one,” says Cole.

The rise and fall of TB treatment

Tuberculosis is not a disease of the past. Infections take 1.4 million lives every year, with the majority of those cases occurring in Asia and Africa. Drug-resistant strains of TB from places like India and the former Soviet Union are a global threat to public health, often brought to new countries by immigrant populations. More alarmingly, several strains have been discovered that are totally impervious to all currently available treatments. Once a resistant strain infects a human, there is little hope for survival.

Today’s antibiotic dilemma can be traced back to the 1950s, when a new synthetic compound called “isoniazid” proved to be extremely effective against the malady. Nevertheless, with the recent onset of isoniazid-resistant strains, proper treatment involves four drugs and can last up to two years. Isoniazid has lost its status as the TB wonder drug.

New drug target, new hope

“We have discovered what’s known in the pharmaceutical world as a new drug target, opening the door for the development of new drugs and therapies that attack the same mechanism,” explains Cole.

Looking for a drug that will kill isoniazid-resistant strains led Stewart Cole on an investigative journey into the past. With a combination of scientific foresight and serendipity, Cole found pyridomycin, an antibiotic extracted from a soil microbe. It was discovered around the same time as isoniazid but was left by the wayside for 60 years.

Cole and his team found that the once-discarded antibiotic, like isoniazid, attacks one of the bacteria’s strongholds—the production of a fatty component in cell walls called mycolic acid. Mycolic acid protects the bacteria from traditional medical onslaughts by helping it weather short treatments or even hiding the microbial invader from the immune system. But Pyridomycin attacks the enzyme from a different entry point, meaning it kills isoniazid-resistant bacteria.

Going back to Nature for a cure

Perhaps even more important than the potential for pyridomycin to combat drug-resistant strains of TB is the strategy that this approach evokes. Back in the 1970s, researchers and clinicians were very excited about synthetic drugs that were easy to make. Now, drug-resistant strains could force scientists to go back to naturally occurring compounds, no matter how difficult they are to make. Going back to look for unused natural antibiotics dips into a largely untapped pool of bioactive compounds, providing the potential to revive a floundering pharmaceutical sector by uncovering new medicines to treat drug-resistant strains of M. tuberculosis and other bacteria.

For the next phase of his research Cole is currently collaborating with Professor Karl-Heinz Altmann at the ETH Zürich to synthesize pyridomycin and increase its availability to researchers with the eventual goal of beginning clinical trials. “To purify and synthesize pyridomycin from bacteria is the chemist’s equivalent of climbing Mount Everest,” says Cole, who is nevertheless confident that Altmann’s team has cracked the chemical synthesis problem.

****

Towards a new tuberculosis drug: Pyridomycin – Nature’s isoniazid

Ruben C Hartkoorn, Claudia Sala, João Neres, Florence Pojer, Sophie J. Magnet, Raju Mukherjee, Swapna Uplekar, Stefanie Boy-Röttger, Karl-Heinz Altmann, Stewart T. Cole

Read the article:

doi: xxx

Researcher contact

Stewart Cole, stewart.cole@epfl.ch, Tel: +41 26 693 1851

Lab website, The Global Health Institute

World Health Organization interactive TB map

Recent Lancet publication of MDR strains of TB

Return to previous page
Alumni
Olivier Glauser
Diplôme
Master en Informatique et systèmes de communication 1994
Parcours
1994 - 1996 HP
1996 - 1998 Phillippe Moris
1998 - 2005 MBA Universite de Harvard
2005 - 2009 ROTH Cl Partners
Fonction
Directeur général de Streamboat Ventures, Pékin

Contacts

Olivier Gauser
Steamboat Ventures
222 Hu Bin Road, Shanghai 200021
Tel: 86 (21) 2308 1800
olivier.glauser@steamboatvc.com
A3 EPFL
Rolex Learning Center
Case postale 122
1015 Lausanne 15
Tel: +41 (0)21 693 24 91